Tags : Imvexxy

Theramex Signs an Exclusive License Agreement with Therapeutics MD to

Shots: Therapeutics MD to receive $15.82M upfront, $33.34M milestones including $2.26M as regulatory milestones & $31.08M as commercial milestones and royalties on sales in licensed territories Theramex to get exclusive commercialization rights for Bijuva and Imvexxy outside the US and is responsible for all regulatory and commercial activities in the licensed territories. Additionally, Therapeutics MD […]Read More